Strategic focus Target rare and serious diseases with a delivery technology (TPE) to position Chiasma as a partner for patients seeking non-injectable options, aligning BD efforts with payer and provider initiatives focused on patient independence and treatment convenience.

Expansion signals Note the company’s partial acquisition history and potential for integration opportunities with larger rare-disease portfolios, suggesting fertile ground for channel partnerships, co-development deals, or distribution arrangements to widen market reach.

Regulatory momentum Leverage ongoing and recent marketing authorization efforts for Mycapssa in Europe as a pathway to cross-sell related oral therapies, leveraging existing regulatory milestones to approach European pharma and specialty care networks.

Clinical validation Highlight strong patient-reported outcomes and quality-of-life improvements from MPOWERED trials to support value-based selling with clinicians, payers, and patient advocacy groups seeking meaningful impact metrics.

Commercial readiness Even with modest current revenue, emphasize near-term opportunities in contract manufacturing, supply chain partnerships for oral capsule production, and digital engagement platforms to scale clinician and patient outreach.